The indolocarbazole analogue CEP-751 is a potent and selective tyrosine kinase inhibitor of the neurotrophin-specific trk receptors that has demonstrated antitumor activity in nine different models of prostate cancer growth in vivo. In the slow-growing, androgen-sensitive Dunning H prostate cancers, which express trk receptors, CEP-751 induced transient regressions independent of effects on cel...

Article history: Received 23 October 2007 Received in revised form 21 February 2008 Accepted 25 February 2008 Available online xxxx EC TE D PR Reproductive hormones have been demonstrated tomodulate both gapand tight-junctionprotein expression in reproductive tissues and endometrium,however the effects of changes in reproductive hormoneson the selective permeability of the blood-brain barrier (...

Abstract Objectives Gonadotropin-releasing hormone agonist treatment is important for optimal growth in girls with central precocious puberty (CPP). Data are lacking regarding benefit to height outcome when started after chronological age (CA) of 7 years, and if continued beyond CA 10 years or bone (BA) 12 years. Methods Forty-eight CPP were treated monthly leuprolide depot. Change predicted ad...

Reproductive hormones have been demonstrated to modulate both gap and tight junction protein expression in the ovary and other reproductive tissues, however the effects of changes in reproductive hormones on the selective permeability of the blood-brain barrier (BBB) remain unclear. Age-related declines in BBB integrity correlate with the loss of serum sex steroids and increase in gonadotropins...

BACKGROUND Studies comparing the gonadotropin-releasing hormone antagonist, degarelix, with luteinising hormone-releasing hormone (LHRH) agonists indicate differences in outcomes. OBJECTIVE To assess differences in efficacy and safety outcomes in a pooled analysis of trials comparing degarelix with LHRH agonists. DESIGN, SETTING, AND PARTICIPANTS Data were pooled from five prospective, phas...